{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T06:14:22Z","timestamp":1784268862734,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10147-023-02432-9","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:01:35Z","timestamp":1700611295000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Liposomal irinotecan plus fluorouracil\/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study"],"prefix":"10.1007","volume":"29","author":[{"given":"Shuhei","family":"Nagashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2535-6586","authenticated-orcid":false,"given":"Satoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Yamachika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Tozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"2432_CR1","unstructured":"National Cancer Institute (2021) Cancer Stat Facts: Pancreatic Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html Accessed Jan 2022"},{"key":"2432_CR2","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.annonc.2020.02.009","volume":"31","author":"G Carioli","year":"2020","unstructured":"Carioli G, Bertuccio P, Boffetta P et al (2020) European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol 31:650\u2013658. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.009","journal-title":"Ann Oncol"},{"key":"2432_CR3","doi-asserted-by":"publisher","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","volume":"5","author":"M Ducreux","year":"2017","unstructured":"Ducreux M, Cuhna AS, Caramella C et al (2017) Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Suppl 5:v56-68. https:\/\/doi.org\/10.1093\/annonc\/mdv295","journal-title":"Ann Oncol Suppl"},{"key":"2432_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923","journal-title":"N Engl J Med"},{"issue":"18","key":"2432_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369","journal-title":"N Engl J Med"},{"key":"2432_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545\u2013557. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"2432_CR7","unstructured":"Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare). https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html Accessed Apr 2023"},{"key":"2432_CR8","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jgo.2019.02.011","volume":"10","author":"T Macarulla","year":"2019","unstructured":"Macarulla T, Blanc JF, Wang-Gillam A et al (2019) Liposomal irinotecan and 5-fluorouracil\/leucovorin in older patients with metastatic pancreatic cancer-a subgroup analysis of the pivotal NAPOLI-1 trial. J Geriatr Oncol 10:427\u2013435. https:\/\/doi.org\/10.1016\/j.jgo.2019.02.011","journal-title":"J Geriatr Oncol"},{"key":"2432_CR9","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1002\/cam4.3558","volume":"9","author":"M Ueno","year":"2020","unstructured":"Ueno M, Nakamori S, Sugimori K et al (2020) nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients. Cancer Med 9:9396\u20139408. https:\/\/doi.org\/10.1002\/cam4.3558","journal-title":"Cancer Med"},{"key":"2432_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2432_CR11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed Nov 2023"},{"key":"2432_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.dld.2015.11.001","volume":"48","author":"N Le","year":"2016","unstructured":"Le N, Sund M, Vinci A et al (2016) Prognostic and predictive markers in pancreatic adenocarcinoma. Dig Liver Dis 48:223\u2013230. https:\/\/doi.org\/10.1016\/j.dld.2015.11.001","journal-title":"Dig Liver Dis"},{"key":"2432_CR13","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","volume":"66","author":"DC Drummond","year":"2006","unstructured":"Drummond DC, Noble CO, Guo Z et al (2006) Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66:3271\u20133277. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4007","journal-title":"Cancer Res"},{"key":"2432_CR14","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1007\/s10147-019-01511-0","volume":"24","author":"R Hasegawa","year":"2019","unstructured":"Hasegawa R, Okuwaki K, Kida M et al (2019) A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer. Int J Clin Oncol 24:1574\u20131581. https:\/\/doi.org\/10.1007\/s10147-019-01511-0","journal-title":"Int J Clin Oncol"},{"key":"2432_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/MPA.0000000000001484","volume":"49","author":"S Kobayashi","year":"2020","unstructured":"Kobayashi S, Ueno M, Ikeda, et al (2020) A multicenter retrospective study of gemcitabine plus nab-paclitaxel for elderly patients with advanced pancreatic cancer. Pancreas 49:187\u2013192. https:\/\/doi.org\/10.1097\/MPA.0000000000001484","journal-title":"Pancreas"},{"key":"2432_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jgo.2021.06.011","volume":"13","author":"F Koga","year":"2022","unstructured":"Koga F, Kawaguchi Y, Shimokawa M et al (2022) Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: a post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study). J Geriatr Oncol 13:82\u201387. https:\/\/doi.org\/10.1016\/j.jgo.2021.06.011","journal-title":"J Geriatr Oncol"},{"key":"2432_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejca.2020.11.003","volume":"143","author":"GW Prager","year":"2021","unstructured":"Prager GW, Oehler L, Gerger A et al (2021) Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: analysis of a multicentre, prospective, non-interventional study. Eur J Cancer 143:101\u2013112. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.003","journal-title":"Eur J Cancer"},{"key":"2432_CR18","doi-asserted-by":"publisher","first-page":"e1516","DOI":"10.1634\/theoncologist.2019-0701","volume":"25","author":"J Feliu","year":"2020","unstructured":"Feliu J, Jim\u00e9nez-Mun\u00e1rriz B, Basterretxea L et al (2020) Predicting chemotherapy toxicity in older patients with cancer: a multicenter prospective study. Oncologist 25:e1516\u2013e1524. https:\/\/doi.org\/10.1634\/theoncologist.2019-0701","journal-title":"Oncologist"},{"key":"2432_CR19","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado CM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920\u20132926. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242","journal-title":"Clin Cancer Res"},{"key":"2432_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/MPA.0000000000001985","volume":"51","author":"H Asama","year":"2022","unstructured":"Asama H, Ueno M, Kobayashi S et al (2022) Sarcopenia: prognostic value for unresectable pancreatic ductal adenocarcinoma patients treated with gemcitabine plus nab-paclitaxel. Pancreas 51:148\u2013152. https:\/\/doi.org\/10.1097\/MPA.0000000000001985","journal-title":"Pancreas"},{"key":"2432_CR21","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CM Prado","year":"2007","unstructured":"Prado CM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264\u20133268. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3067","journal-title":"Clin Cancer Res"},{"key":"2432_CR22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pan.2020.10.029","volume":"21","author":"C Li-Tzong","year":"2021","unstructured":"Li-Tzong C, Teresa M, Jean-Fr\u00e9d\u00e9ric B et al (2021) Early dose reduction\/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): a post hoc analysis of NAPOLI-1. Pancreatology 21:192\u2013199. https:\/\/doi.org\/10.1016\/j.pan.2020.10.029","journal-title":"Pancreatology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02432-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02432-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T22:06:06Z","timestamp":1706133966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02432-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2432"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02432-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2947171\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"17 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that (i) no support, financial or otherwise, has been received from any organization that may have an interest in the submitted work, and (ii) there are no other relationships or activities that could appear to have influenced the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}